BioAge Labs (BIOA) Net Equity Issued and Repurchased (2024 - 2026)
BioAge Labs (BIOA) reported Net Equity Issued and Repurchased of $124.3 million for Q1 2026, down 26.87% sequentially from $170.0 million in Q1 2024.
BioAge Labs (BIOA) Net Equity Issued and Repurchased (2024 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $124.3 million in Q1 2026.
- For the quarter ending Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $124.3 million; the trailing twelve-month figure through Mar 2026 stood at $124.3 million (changed N/A YoY), and the FY2024 full-year result was $170.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased slipped to $124.3 million in Q1 2026, from $170.0 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $170.0 million in Q1 2024 to a low of $124.3 million in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | BioAge Labs | 930.32 Mn | 930.32 Mn | -10.37 Mn | 124.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124.32 Mn |
| Mar 31, 2026 | 124.32 Mn |
| Mar 31, 2024 | 170.00 Mn |
| Mar 31, 2024 | 170.00 Mn |